Related Experiment Video
Updated: May 9, 2026
Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
Published on: May 23, 2025
Photopneumatic therapy for the treatment of keratosis pilaris
Heather Ciliberto1, Arta Farshidi, David Berk
1Department of Internal Medicine, Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA.
Background:
Current treatment options for keratosis pilaris (KP) are limited and are often found to be unsatisfactory to patients.
Objective:
Pilot study to determine if photopneumatic therapy (PPx) can improve the erythema and skin texture in KP.
Methods:
Ten patients with KP were treated with one session of PPx on the upper arm and then evaluated one month later for treatment efficacy.
Results:
Average investigator-assessed improvement was 27% in erythema and 56% in skin texture roughness. Average patient self-reported improvement was 52% in erythema and 53% in skin texture. The mean satisfaction score was 6.3 on a scale of 1 to 10 (median 7.5) and 8 out of 10 participants reported they would choose to receive PPx for their KP again in the future.
Limitations:
Small number of patients, short follow-up period, and lack of blinding of the examiner and the patients making recall bias possible.
Conclusions:
One treatment of PPx improved both the erythema and redness associated with KP over at least a one month period.
Related Concept Videos
01:24Chest Physiotherapy
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...